Table 2.
Characteristics of patients with HIV RNA viral load ≥50 copies/mL at INSTI initiation, stratified by ART regimen.
| Characteristic at INSTI initiation | EVG/COBI + ≥2 NRTIs (N=64) |
DTG + ≥2 NRTIs (N=61) |
RAL + ≥2 NRTIs (N=65) |
RAL + PI1 (N=70) |
Other (N=67) |
P2 |
|---|---|---|---|---|---|---|
| N (%) or median (IQR) | N (%) or median (IQR) | N (%) or median (IQR) | N (%) or median (IQR) | N (%) or median (IQR) | ||
| Sexual risk group | 0.10 | |||||
| MSM | 36 (56%) | 26 (43%) | 30 (46%) | 19 (27%) | 26 (39%) | |
| Women | 16 (25%) | 18 (30%) | 21 (32%) | 28 (40%) | 21 (31%) | |
| Heterosexual men | 12 (19%) | 17 (28%) | 14 (22%) | 23 (33%) | 20 (30%) | |
| IDU | 4 (6%) | 6 (10%) | 6 (9%) | 7 (10%) | 6 (9%) | 0.95 |
| Race/ethnicity | ||||||
| African American | 46 (72%) | 37 (61%) | 33 (51%) | 48 (69%) | 43 (64%) | 0.16 |
| White | 11 (17%) | 16 (26%) | 26 (40%) | 15 (21%) | 20 (30%) | |
| Hispanic/other | 7 (11%) | 8 (13%) | 6 (9%) | 7 (10%) | 4 (6%) | |
| Age, years | 36 (28, 48) | 45 (36, 57) | 42 (33, 48) | 45 (38, 53) | 47 (42, 52) | <0.01 |
| Calendar year | 2014 (2013, 2015) | 2015 (2014, 2016) | 2011 (2009, 2012) | 2009 (2008, 2010) | 2009 (2008, 2011) | <0.01 |
| Years since first ART | 5 (2, 10) | 8 (4, 13) | 9 (2, 13) | 10 (5, 14) | 12 (9, 15) | <0.01 |
| Prior ARV drugs | 4 (3, 6) | 5 (3, 8) | 5 (4, 8) | 8 (6, 12) | 10 (7, 13) | <0.01 |
| Prior ART regimens | 2 (1, 4) | 3 (2, 5) | 3 (2, 5) | 5 (4, 9) | 9 (4, 15) | <0.01 |
| Nadir CD4 count, cells/μL | 227 (63, 355) | 152 (33, 312) | 135 (46, 297) | 28 (9, 108) | 22 (9, 15) | <0.01 |
| CD4 count, cells/μL | 388 (187, 541) | 357 (191, 545) | 315 (141, 541) | 203 (56, 397) | 178 (69, 326) | <0.01 |
| HIV RNA, log10 copies/mL | 4.04 (2.84, 4.60) | 3.75 (2.71, 4.94) | 4.05 (2.92, 4.77) | 4.35 (3.29, 5.17) | 4.51 (3.49, 4.90) | 0.20 |
| Last prior regimen anchor class | <0.01 | |||||
| NNRTI | 27 (42%) | 29 (48%) | 26 (40%) | 17 (24%) | 8 (12%) | |
| PI | 34 (53%) | 29 (48%) | 32 (49%) | 45 (64%) | 39 (58%) | |
| NNRTI and PI | 1 (2%) | 1 (2%) | 1 (2%) | 0 (0%) | 8 (12%) | |
| EI3 | 0 (0%) | 0 (0%) | 0 (0%) | 4 (6%) | 8 (12%) | |
| Other | 2 (3%) | 2 (3%) | 6 (9%) | 4 (6%) | 4 (6%) | |
| Genotype performed at INSTI initiation | 22 (34%) | 22 (36%) | 22 (34%) | 31 (44%) | 25 (37%) | 0.74 |
| Fully active NRTI backbone4 | 20 (91%) | 17 (77%) | 18 (82%) | N/A | N/A | 0.60 |
Abbreviations. ART: antiretroviral therapy. ARV: antiretroviral. COBI: cobicistat. DTG: dolutegravir. EI: entry inhibitor. EVG: elvitegravir. IDU: injection drug use. INSTI: integrase strand transfer inhibitor. IQR: interquartile range. MSM: men who have sex with men. PI: protease inhibitor. N/A: not applicable. NNRTI: non-nucleoside analog reverse transcriptase inhibitor. NRTI: nucleoside analog reverse transcriptase inhibitor. RAL: raltegravir. VL: viral load.
With or without any NRTI agent.
P values from the Monte Carlo estimate of Fisher’s Exact test for categorical variables and the Kruskal-Wallis test for continuous variables.
May include another anchor drug.
Restricted to patients on a single anchor agent and with a genotype performed at INSTI initiation. Based on mutations from all available genotype testing prior to INSTI initiation, interpreted according to the Stanford algorithm. NRTI backbones in which no agent had a resistance score of intermediate or above were considered fully active.